The Economics of Reproducibility in Preclinical Research.
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-06-01
|
| Series: | PLoS Biology |
| Online Access: | http://europepmc.org/articles/PMC4461318?pdf=render |
| id |
doaj-0db2acf4a1554ce4adfcbbc7f08e51ac |
|---|---|
| record_format |
Article |
| spelling |
doaj-0db2acf4a1554ce4adfcbbc7f08e51ac2021-07-02T04:00:38ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852015-06-01136e100216510.1371/journal.pbio.1002165The Economics of Reproducibility in Preclinical Research.Leonard P FreedmanIain M CockburnTimothy S SimcoeLow reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.http://europepmc.org/articles/PMC4461318?pdf=render |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Leonard P Freedman Iain M Cockburn Timothy S Simcoe |
| spellingShingle |
Leonard P Freedman Iain M Cockburn Timothy S Simcoe The Economics of Reproducibility in Preclinical Research. PLoS Biology |
| author_facet |
Leonard P Freedman Iain M Cockburn Timothy S Simcoe |
| author_sort |
Leonard P Freedman |
| title |
The Economics of Reproducibility in Preclinical Research. |
| title_short |
The Economics of Reproducibility in Preclinical Research. |
| title_full |
The Economics of Reproducibility in Preclinical Research. |
| title_fullStr |
The Economics of Reproducibility in Preclinical Research. |
| title_full_unstemmed |
The Economics of Reproducibility in Preclinical Research. |
| title_sort |
economics of reproducibility in preclinical research. |
| publisher |
Public Library of Science (PLoS) |
| series |
PLoS Biology |
| issn |
1544-9173 1545-7885 |
| publishDate |
2015-06-01 |
| description |
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures. |
| url |
http://europepmc.org/articles/PMC4461318?pdf=render |
| work_keys_str_mv |
AT leonardpfreedman theeconomicsofreproducibilityinpreclinicalresearch AT iainmcockburn theeconomicsofreproducibilityinpreclinicalresearch AT timothyssimcoe theeconomicsofreproducibilityinpreclinicalresearch AT leonardpfreedman economicsofreproducibilityinpreclinicalresearch AT iainmcockburn economicsofreproducibilityinpreclinicalresearch AT timothyssimcoe economicsofreproducibilityinpreclinicalresearch |
| _version_ |
1721340753058201600 |